Alarming Plasmodium falciparum resistance to artemisinin-based combination therapy in Africa: the critical role of the partner drug

Lancet Infect Dis. 2024 Sep;24(9):e540-e541. doi: 10.1016/S1473-3099(24)00427-4. Epub 2024 Jul 22.

Authors

Anders Björkman¹, Pedro Gil², Michael Alifrangis³

Affiliations

¹ Department of Global Public Health, Tumor and Cell Biology, Karolinska Institutet, 17176 Stockholm, Sweden. Electronic address: anders.bjorkman@ki.se.
² Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, 17176 Stockholm, Sweden.
³ Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark; Department of Infectious Diseases, Copenhagen University Hospital, Copenhagen, Denmark.

PMID: 39053482
DOI: 10.1016/S1473-3099(24)00427-4

No abstract available

Publication types

Letter

MeSH terms

Africa / epidemiology
Antimalarials* / therapeutic use
Artemisinins* / therapeutic use
Drug Resistance*
Drug Therapy, Combination*
Humans
Malaria, Falciparum* / drug therapy
Plasmodium falciparum* / drug effects

Substances

Artemisinins
Antimalarials
artemisinin